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Methamphetamine (Meth) is a widely abuse psychostimulant. Traditionally, studies have
focused on the neurotoxic effects of Meth on monoaminergic neurotransmitter terminals.
Recently, both in vitro and in vivo studies have investigated the effects of Meth on the BBB
and found that Meth produces a decrease in BBB structural proteins and an increase in
BBB permeability to various molecules. Moreover, preclinical studies are validated by
clinical studies in which human Meth users have increased concentrations of toxins in
the brain. Therefore, this review will focus on the structural and functional disruption
of the BBB caused by Meth and the mechanisms that contribute to Meth-induced BBB
disruption. The reviewwill reveal that themechanisms by whichMeth damages dopamine
and serotonin terminals are similar to the mechanisms by which the blood-brain barrier
(BBB) is damaged. Furthermore, this review will cover the factors that are known to
potentiate the effects of Meth (McCann et al., 1998) on the BBB, such as stress and
HIV, both of which are co-morbid conditions associated with Meth abuse. Overall, the
goal of this review is to demonstrate that the scope of damage produced by Meth goes
beyond damage to monoaminergic neurotransmitter systems to include BBB disruption
as well as provide a rationale for investigating therapeutics to treat Meth-induced BBB
disruption. Since a breach of the BBB can have a multitude of consequences, therapies
directed toward the treatment of BBB disruption may help to ameliorate the long-term
neurodegeneration and cognitive deficits produced by Meth and possibly even Meth
addiction.
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Introduction
Methamphetamine (Meth) is a widely abused psychostimulant that causes long-term monoamine
neurotransmitter depletions. The well-establishedmechanisms responsible forMeth-induced dam-
age tomonoaminergic terminals are not selective but likely target other cell types and tissues as well.
In this review, the focus will be on the effects of Meth and comorbid factors on blood-brain barrier
(BBB) structure and function and how the mechanisms of Meth-induced monoaminergic damage
can also contribute to BBB damage. In addition, potential consequences of Meth-induced BBB dis-
ruption and the importance of further research regarding Meth-induced BBB disruption will be
discussed.
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Meth-Induced Neurotoxicity
Meth produces long-term neuronal damage in humans, non-
human primates and rodents. Positron emission tomography
(PET) and proton magnetic resonance spectroscopy (MRS) stud-
ies in abstinent human Meth users indicate damage to the
dopaminergic and serotonergic systems, marked by decreases
in the dopamine (DA) and serotonin (5-HT) transporters, DAT
(McCann et al., 1998; Volkow et al., 2001a,b) and SERT (Sekine
et al., 2006), which can last up to 3 years after the end ofMeth use.
PET and MRI observations in abstinent Meth users are substan-
tiated by studies of human postmortem brain tissue and rodent
studies. Postmortem studies of brains from chronic Meth users
as well as rodents exposed to Meth, illustrate decreases in DA,
tyrosine hydroxylase (TH), tryptophan hydroxylase (TPH), vesic-
ular monoamine transporter -2 (VMAT-2), DAT and SERT, in
areas highly innervated by DA and 5-HT terminals (Hotchkiss
and Gibb, 1980; Ricaurte et al., 1980; Wagner et al., 1980; Wilson
et al., 1996; Cass and Manning, 1999; Moszczynska et al., 2004;
Eyerman and Yamamoto, 2007; Kitamura et al., 2007; Kish et al.,
2009).
While the traditional belief is that Meth selectively dam-
ages DA and 5-HT axon terminals, more recent studies sug-
gest that Meth produces more widespread damage. Meth users
have decreases in the neuronal marker, N-acetylaspartate (Ernst
et al., 2000; Chang et al., 2005), which is a more general indi-
cation of injury. In addition, rodent studies have shown that
Meth produces damage to cell bodies evidenced by increased
caspase-mediated proteolysis and TUNEL staining in the stria-
tum and hippocampus (Schmued and Bowyer, 1997; Deng et al.,
2001; Warren et al., 2005). Moreover, a study by Zhu et al.
(2006) observed that parvalbumin-positive γ-aminobutyric acid
(GABA) interneurons and cholinergic interneurons in the stria-
tum undergo apoptosis after a single administration of 30mg/kg
Meth to mice. Meth binge treatment also decreases the num-
ber of glutamatergic neurons in the somatosensory cortex (Pu
et al., 1996). Therefore, the toxic effects of Meth extend beyond
dopaminergic and serotonergic terminals but the mechanisms
mediating those effects remain to be determined.
Mechanisms of Monoamine Damage
Many studies have investigated the mechanisms responsible for
monoamine neurotransmitter damage caused by Meth. Those
mechanisms include hyperthermia, neurotransmitter release,
oxidative stress, mitochondrial dysfunction and inflammation.
Hyperthermia is an acute effect of Meth and appears nec-
essary but is not sufficient to cause monoaminergic damage
(Bowyer et al., 1992, 1994; Xie et al., 2000). This is evidenced
by the fact that Meth-induced monoaminergic terminal dam-
age is not observed in rodents that are placed in a setting
with low ambient temperature and do not experience Meth-
induced hyperthermia (Bowyer et al., 1992, 1994). Furthermore,
pharmacological interventions that attenuate hyperthermia also
attenuate Meth-induced monoaminergic damage. For exam-
ple, antagonism of NMDA receptors using MK-801 or D1 or
D2 dopaminergic receptors using SCH23390 and haloperidol,
respectively, prevents Meth-induced hyperthermia and toxicity
(Bowyer et al., 1994; Albers and Sonsalla, 1995). In contrast, sev-
eral studies suggest that hyperthermia is not the sole mechanism
since pharmacological interventions that do not alter hyperther-
mia will attenuate Meth toxicity (Itzhak et al., 2000; Ladenheim
et al., 2000; Callahan et al., 2001; Sanchez et al., 2003).
Neurotransmitter release is a well-known acute effect of Meth.
Meth increases extracellular concentrations of DA and gluta-
mate (Raiteri et al., 1979; Mark et al., 2004). A consequence of
these increases in cytosolic DA and extracellular glutamate is the
generation of reactive oxygen species (ROS) and reactive nitro-
gen species (RNS). MAO metabolism of DA to DOPAC as well
as autoxidation of DA results in the formation of ROS (Gra-
ham et al., 1978; Spina and Cohen, 1989; Hastings et al., 1996;
Alper et al., 1999; Lavoie and Hastings, 1999). On the other hand,
increased extracellular glutamate activates its calcium permeable
receptors and results in the activation of nitric oxide synthase
(NOS) (Dawson et al., 1991) and subsequent reactive nitrogen
species (RNS) (Obata, 2002).
The role of ROS and RNS in Meth-induced monoamin-
ergic terminal damage is well-established. Antioxidants such
as N-acetyl-L-cysteine, ascorbic acid and vitamin E and NOS
inhibitors attenuate Meth-induced striatal DA and 5-HT deple-
tions (Wagner et al., 1985; De Vito and Wagner, 1989; Abekawa
et al., 1996; Imam et al., 2001a; Fukami et al., 2004; Eyerman and
Yamamoto, 2007). In addition, administration of Meth to mice
overexpressing copper/zinc superoxide dismutase (Cu/ZnSOD)
or manganese superoxide dismutase (MnSOD), enzymes respon-
sible for eliminating superoxide radicals, or neuronal nitric oxide
synthase (nNOS) knockout mice does not result in striatal dam-
age (Cadet et al., 1994a,b; Hirata et al., 1995; Itzhak et al.,
1998; Maragos et al., 2000; Imam et al., 2001b). In contrast, an
SOD inhibitor enhances Meth-induced DA and 5-HT depletions
in the rat striatum (De Vito and Wagner, 1989). Collectively,
these data support the role of oxidative stress in Meth-induced
neurotoxicity.
Excess extracellular glutamate can damage monoamine termi-
nals independent of nNOS. Upon activation of its calcium perme-
able NMDA or AMPA receptors, glutamate results in an increase
in intracellular calcium, which in turn activates calcium depen-
dent enzymes and ultimately leads to cellular damage. In fact,
Meth administration results in calpain-mediated spectrin prote-
olysis, which is associated with damage to striatal DA terminals
(Staszewski and Yamamoto, 2006). In addition, it has been shown
that inhibition of glutamate release from corticostriatal path-
ways or blockade of glutamate receptors prevents Meth-induced
damage to striatal DA terminals (Sonsalla et al., 1991; Stephans
and Yamamoto, 1994; Battaglia et al., 2002; Mark et al., 2004).
Therefore, multiple studies support the role of excitotoxicity in
Meth-induced monoaminergic terminal damage.
More recently, it was observed that Meth damages the liver,
which can release factors known to mediate brain damage as in
the case of hepatic encephalopathy. Binge Meth administration
results in liver damage and consequent increases in circulating
ammonia (Halpin and Yamamoto, 2012). Brain concentrations of
ammonia are also elevated after Meth exposure and contribute to
Meth-induced increases in extracellular glutamate (Halpin and
Frontiers in Neuroscience | www.frontiersin.org 2 March 2015 | Volume 9 | Article 69
Northrop and Yamamoto Meth blood-brain barrier
Yamamoto, 2012; Halpin et al., 2014). Intrastriatal injection of
the combination of Meth and ammonia produce decreases in
monoamine tissue content that are prevented by the glutamate
receptor AMPA antagonist, GYKI 52466 (Halpin and Yamamoto,
2012). In addition, treatment with an ammonia scavenger, lac-
tulose, that is limited to the gut and does not enter the brain,
attenuates Meth-induced monoamine depletions (Halpin and
Yamamoto, 2012). These data together provide evidence that
Meth not only damages the brain, but also damages peripheral
organs, and the resulting increases in circulating ammonia con-
tributes to Meth-induced monoaminergic damage in a glutamate
dependent manner.
Mitochondrial dysfunction or bioenergetic stress is another
mechanism by which Meth causes toxicity. Meth results in a
depletion of ATP (Chan et al., 1994) and inhibits complex II
of the electron transport chain (Brown et al., 2005) whereas
treatment with the mitochondrial complex substrates, decylu-
biquinone or nicotinamide, after Meth treatment, attenuates
Meth-induced striatal DA depletions (Stephans et al., 1998).
Thus, a bioenergetic compromise and mitochondrial dysfunc-
tion play a role in Meth-induced monoaminergic terminal
damage.
Less clear is the direct role of inflammation in Meth-induced
monoaminergic terminal damage. Meth-induced monoaminer-
gic damage is associated with neuroinflammation in humans and
rodents. Recent PET scans of human Meth users indicate promi-
nent microglial activation (Chang et al., 2002; Sekine et al., 2008)
and chronic Meth users present with increased plasma cytokines
and chemokines (Loftis et al., 2011). These observations are sub-
stantiated by preclinical studies that also observe glial activation
(Escubedo et al., 1998; Lavoie et al., 2004; Thomas et al., 2004a,c)
and increases in inflammatory mediators (Yamaguchi et al., 1991;
Flora et al., 2002; Thomas et al., 2004b; Goncalves et al., 2008;
Loftis et al., 2011) in various brain regions, including the hip-
pocampus and striatum after Meth administration. Microglial
activation is closely associated with Meth-induced monoamin-
ergic damage and lack of microglial activation is typically asso-
ciated with lack of monoaminergic damage (Lavoie et al., 2004;
Thomas et al., 2004a,c). In addition, indomethacin attenuates
microglial activation and decreases in beta III tubulin expres-
sion produced by Meth but monoaminergic depletions were not
investigated (Goncalves et al., 2010). In contrast, microglial acti-
vation may be a consequence of Meth-induced damage, not lim-
ited to monoaminergic damage. The role of individual cytokines
is less clear. Meth-induced monoaminergic terminal damage is
prevented in IL-6 knockout mice (Ladenheim et al., 2000), sug-
gesting a harmful role for IL-6. In contrast, intrastriatal injections
of TNF-α attenuate rather than enhance Meth-induced decreases
in DA and tyrosine hydroxylase (Nakajima et al., 2004), sug-
gesting a protective role for TNF-α. Furthermore, Meth-induced
DA depletions are still observed in TNF-α and COX-2 knockout
mice, when Meth-induced hyperthermia is maintained (Naka-
jima et al., 2004; Thomas and Kuhn, 2005). Therefore, there is
a tenuous relationship between inflammation and monoaminer-
gic damage produced by Meth and the role of neuroinflamma-
tion in Meth-induced monoaminergic terminal damage warrants
further investigation.
In summary, there is clear evidence that the acute effects
of Meth, including hyperthermia, oxidative stress, excitotoxic-
ity and mitochondrial dysfunction play a role in Meth-induced
monoamine terminal damage. Research has focused primarily on
the dopaminergic and serotonergic systems because of the direct
pharmacological actions of Meth at DAT and SERT. However,
the mechanisms responsible for monoaminergic damage are not
specific for only neurons and likely cause damage to other cells
in the brain. One class of cells that can be damaged by these
mechanisms is those that which comprise the BBB.
Mechanisms of BBB Damage
The BBB can be disrupted by similar mechanisms that are
responsible for Meth-induced monoaminergic damage and par-
allel those that are known to cause BBB disruption in a variety of
other neurological diseases.
Extreme changes in body temperature are associated with
increased BBB permeability. Kiyatkin and Sharma (2009)
reported that both hyperthermia and hypothermia alter BBB
function. Brains of rats, warmed to reach temperatures of
38.5–42◦C, showed increases in albumin, GFAP-positive cells,
water content and sodium, potassium and chloride concentra-
tions, suggestive of brain edema. Moreover, the extent of BBB
disruption was correlated with body temperature. Microwave-
induced brain hyperthermia also results in horseradish peroxi-
dase extravasation into the brain when brain temperatures were
heated and maintained at 44.3◦C for 30min and 42.5◦C for
60min (Moriyama et al., 1991). Similarly, brain temperatures
measured at hypothermic temperatures of 32–33◦C also pro-
duced BBB leakage but to a lesser extent than hyperthermia
(Kiyatkin and Sharma, 2009) and did not result in increases
in brain water or ion content. These data suggest that alter-
ations in brain temperatures alone can increase permeability of
the BBB.
The role of oxidative stress in BBB disruption has been well-
characterized. Oxidative stress is associated with BBB disruption
in a variety of neurodegenerative disorders that have concomi-
tant BBB disruption. Moreover, attenuation of oxidative dam-
age is associated with protection against BBB damage (Kamada
et al., 2007; Sharma et al., 2007; Ji et al., 2010, 2012; Price et al.,
2012; Zehendner et al., 2013). Cerebrovascular endothelial cells
in culture are damaged by 4-hydroxynonenal (HNE) (Karlhu-
ber et al., 1997) and oxidized low-density lipoprotein (LDL),
both of which are prevented by the antioxidant, resveratrol (Lin
et al., 2010). Additionally, the free radical scavenger, edaravone,
prevents oxidative stress, decreases in the BBB structural tight
junction protein occludin, and increased BBB permeability to
sodium-fluorescein produced by tissue plasminogen activator
(tPA) in rats (Lukic-Panin et al., 2010). Furthermore, transgenic
mice overexpressing copper/zinc superoxide dismutase are resis-
tant to ischemia-induced free radical production and Evans blue
leakage (Kim et al., 2001). In contrast, decreased copper/zinc
superoxide dismutase activity enhances ischemia-induced edema
in mice (Kondo et al., 1997). Together these findings illustrate a
prominent role for oxidative stress in BBB damage after a variety
of insults.
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Mitochondrial dysfunction produces ROS and is also associ-
ated with BBB disruption in the context of Parkinson’s Disease
(PD) and Huntington’s Disease (HD). Intrastriatal injection of
the mitochondrial toxin 3-nitropropionic acid (3-NP), used as
a model of HD, produced extravasation of Evans blue into the
brain parenchyma as early as 3 h after administration of 3-NP
while Evans blue extravasation and increased brain water content
persisted for as long as 3 days after intrastriatal administration of
3-NP (Sato et al., 1997).
Excess extracellular glutamate can also lead to ROS and
RNS production and possibly BBB disruption. Activation of
ionotropic calcium permeable glutamate receptors, such as
NMDA and AMPA receptors, results in an increase in intracel-
lular calcium and subsequent activation of caspases and calpains
as well as production of nitric oxide and reactive oxygen species
(Siman and Noszek, 1988; Izumi et al., 1992). Consequently,
increases in extracellular glutamate can be toxic to brain endothe-
lial cells since they express NMDA receptors (Krizbai et al., 1998)
and respond with increases in calcium influx and oxidative stress
(Sharp et al., 2005; Neuhaus et al., 2011). In addition, exposure
to glutamate decreases expression of the brain endothelial cell
transmembrane protein, occludin (Andras et al., 2007; Neuhaus
et al., 2011). Furthermore, increases in BBB permeability have
been observed in response to seizure activity produced by a vari-
ety of convulsive agents (Nitsch and Klatzo, 1983; Pont et al.,
1995) but it is unclear whether BBB disruption is a cause or conse-
quence of seizure activity (for review, see Oby and Janigro, 2006).
Thus, while excess extracellular glutamate likely contributes to
BBB disruption, further studies are required to determine the role
of glutamate in BBB disruption.
Lastly, inflammation is associated with BBB disruption. For
example, the quintessential neuroinflammatory disease, Multiple
Sclerosis (MS), presents with BBB disruption (Kermode et al.,
1990). More specifically, TNFα expression and permeability of
the BBB to endogenous albumin is produced by ischemia and
treatment with an antibody against TNFα, attenuated ischemia-
induced BBB damage (Yang et al., 1999). Pro-inflammatory
mediators, such as cyclooxygenase (COX) also contribute to BBB
disruption. COX inhibitors prevent ischemia- and TBI-induced
BBB disruption (Mohanty et al., 1980; Ting, 1990; Candelario-
Jalil et al., 2007; Hakan et al., 2010). Furthermore, prostaglandins
are products of COX activity and mediate BBB disruption in a
strokemodel through EP1 receptor (EP1R) activation (Fukumoto
et al., 2010). While it is unknown how EP1R activation increases
BBB permeability, it may be through the signal transduction
pathways that activate kinases (Bos et al., 2004) and subsequent
phosphorylation of TJs. In fact, Rho kinase (ROCK) activity is
stimulated by the EP1R (Wolkowicz et al., 2002), phosphory-
lates occludin and claudin-5 in brain endothelial cells (Yamamoto
et al., 2008) and results in the loss of integrity of TJs in HIV-
encephalitis models (Persidsky et al., 2006). Overall, there is sig-
nificant support for the role of inflammation in BBB disruption.
Meth-Induced BBB Damage
More recently, the BBB has been identified as a target ofMeth and
a change in the BBB is thought to be a consequence of the acute
effects of Meth, similar to Meth-induced monoamine terminal
damage. The majority of evidence is provided by preclinical stud-
ies that illustrate the effects of Meth on BBB structural proteins,
the tight junction proteins, as well as BBB function.
Bowyer and Ali (2006) were the first to identify an increase
in BBB permeability to endogenous IgG, as early as 90min after
exposure of rats to a single high dose of Meth, but this effect
seemed to recover by 3 days after Meth exposure. Increases in
IgG were apparent in the hippocampus and amygdala but only
in rats that became hyperthermic and had seizures. Lower doses
of Meth also increase permeability to Evans blue and FITC-
labeled albumin within 24 h of Meth exposure (Kiyatkin et al.,
2007; Kousik et al., 2011). These early increases in BBB perme-
ability may be due to hyperthermia since the extent of increases
in Evans blue and water content in the brain directly correlate
with brain temperature (Kiyatkin et al., 2007). Transient changes
in BBB structures have also been noted after Meth exposure. A
single high dose of Meth to mice decreased expression of BBB
structural tight junction proteins including occludin, claudin-5,
and ZO, 24 h after Meth exposure (Martins et al., 2011). The
mechanism underlying these changes may be associated with an
increase in activated matrix metalloprotease-9 (MMP-9), which
also has been demonstrated to play a major role in inflamma-
tion and ischemia-reperfusion-induced disruption of tight junc-
tion proteins and increase in BBB permeability (Mun-Bryce and
Rosenberg, 1998; Yang et al., 2007). It remains to be determined
whether MMP-9 plays a causative role in Meth-induced BBB
disruption, however, hyperthermia contributes to the acute BBB
disruption observed after a single high dose of Meth.
The contribution of oxidative stress in Meth-induced BBB
disruption has also been studied. Exposure of cultured brain
microvascular endothelial cells to Meth exhibit decreased expres-
sion of occludin, claudin-5 and zona occludens (ZO) as well as
decreased transendothelial electrical resistance (TEER), indica-
tive of increased paracellular permeability (Mahajan et al., 2008;
Ramirez et al., 2009). These alterations in endothelial structures
and function are associated with increases in ROS such that the
antioxidant, Trolox, reduced Meth-induced decreases in TEER
in endothelial cells in culture as well as extravasation of sodium-
fluorescein in mice, observed 2 days after exposure to Meth
(Ramirez et al., 2009).
Cells other than brain microvascular endothelial cells are
responsible for BBB integrity. Astrocytes extend their endfeet to
contact endothelial cells and help to stabilize and maintain BBB
function (for review, see Abbott, 2000). One protein on astro-
cytes, β-dystroglycan, crosslinks astrocytic endfeet to endothe-
lial cells and helps maintain a hydrophobic barrier and regulates
aquaporin 4 (AQP4) localization. Thus, decreased expression of
β-dystroglycan expression or truncation of its full form may pre-
vent the localization of AQP4 to astrocytic endfeet and com-
promise the ability of AQP4 to regulate water clearance in the
brain parenchyma (Papadopoulos et al., 2004). In fact, binge
Meth exposure results in increased truncation of β-dystroglycan
and increases in brain water content at 24 h (Northrop and
Yamamoto, 2012). In addition, Meth acutely damages epithelial
cells of the choroid plexus (Sharma and Kiyatkin, 2009), a struc-
ture involved in regulating water exchange between the brain
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and blood, which could also contribute to Meth-induced brain
edema.
Another cell type that interacts with endothelial cells and helps
to maintain proper BBB function are pericytes. Pericytes main-
tain proper BBB function including induction of tight junction
and basement membrane formation, support of astrocytes in
end-foot distribution and polarization and regulation of blood
flow. Thus, an impairment of pericytes could dysregulate BBB
function (for review, see Winkler et al., 2011). Pericytes can
be damaged via mechanisms similar to those responsible for
Meth-induced disruption of brain endothelial cells. For example,
oxidative damage to pericytes in response to hyperglycemia and
mitochondrial stress cause cell damage that can be prevented by
antioxidant treatment (Price et al., 2012; May et al., 2014; Okada
et al., 2014). Since pericytes express functional NMDA glutamate
receptors (Montiel-Eulefi et al., 2012), they can be activated by
Meth-induced glutamate release and in turn, lead to excitotoxic-
ity. In addition, activation of glutamate receptors produces RNS
and s-nitrosylation activates MMP-2 and MMP-9, two proteases
known to disrupt tight junction proteins (Gu et al., 2002). Fur-
thermore, inflammation may mediate the effects of Meth on per-
icytes as LPS infection can dissociate pericytes from endothelial
cells and the basement membrane and increase BBB permeability
(Nishioku et al., 2009).
Meth-induced peripheral organ damage, such as liver, mus-
cle and kidney, can also lead to BBB disruption. Peripheral organ
damage can lead to increases in circulating and brain ammo-
nia concentrations through increases in brain glutamate (Chan
et al., 2000; Gorg et al., 2010; Halpin et al., 2014). Ammonia
can also induce oxidative stress via superoxide and nitric oxide
production as well as through decreases in antioxidant enzymes
(Kosenko et al., 1997a,b). Consequently, ammonia may result
in oxidative damage of endothelial cells or activation of MMPs.
In addition, excess ammonia can result in neuroinflammation
marked by increases in microglial and astrocytic activation, pro-
inflammatory cytokines and prostaglandin E2 (PGE2) (Rodrigo
et al., 2010; Bemeur and Butterworth, 2012). Thus, ammonia may
also be a contributing factor to Meth-induced BBB damage via
oxidative, excitotoxic and/or inflammatory dependent manners.
Meth Comorbidities
It is important to note that Meth use, similar to other drugs of
abuse, does not occur in isolation. Comorbidities associated with
Meth, including stress disorders, use of other drugs and HIV
infection, may potentiate the effects of Meth on the BBB.
Stress
Stress is highly comorbid with drug use. Stressors increase
ROS (Mcintosh and Sapolsky, 1996; Leza et al., 1998; Madri-
gal et al., 2001), inflammatory mediators (Minami et al., 1991;
Garcia-Bueno et al., 2008), mitochondrial dysfunction (Madri-
gal et al., 2001) and extracellular glutamate (Moghaddam,
1993). As mentioned previously, these mechanisms contribute
to Meth-induced BBB disruption in response to a variety of
insults. Thus, it is likely that stress could exacerbate Meth-
induced BBB disruption by potentiating Meth-induced increases
in ROS, inflammatory mediators, mitochondrial dysfunction,
and extracellular glutamate.
In fact, serial exposure to 10 days of chronic unpredictable
stress (CUS) and Meth produce an enhanced damage of the BBB,
compared to stress or Meth alone at 24 h after Meth exposure.
This damage was evidenced by decreases in the tight junction
proteins, occludin and claudin-5, truncation of the astrocytic
endfeet protein β-dystroglycan, as well as increases in BBB per-
meability to water and 10,000Da FITC-dextran (Northrop and
Yamamoto, 2012). Furthermore, the combination of stress and
Meth but not Meth alone, prolonged BBB disruption in a man-
ner that was paralleled by an increase in inflammatory mark-
ers, GFAP and COX-2, up to 7 days after exposure to stress
and Meth (Northrop and Yamamoto, 2012). In addition, the
non-selective COX inhibitor, ketoprofen, prevented the disrup-
tion in BBB structure and function observed at 7 days, when
ketoprofen was administered after, but not during exposure to
stress and Meth (Northrop and Yamamoto, 2012). This illus-
trates that the combination of stress andMeth produces a delayed
increase in neuroinflammation that is responsible for the pro-
longed breach in the BBB. Therefore, these findings illustrate that
stress enhancesMeth-induced early BBB disruption and prolongs
the opening of the BBB, as compared to Meth alone in a manner
that is dependent on COX activity. Other mechanisms by which
stress can enhance Meth-induced BBB damage, such as oxida-
tive stress, mitochondrial dysfunction and glutamate remain to
be examined.
Ethanol
Ethanol is one drug that is frequently abused in combination with
Meth. Ethanol can directly damage brain microvascular endothe-
lial cells (BMVECs) in culture. Exposure to ethanol produces
activation of myosin light chain kinase and consequent phos-
phorylation and degradation of tight junction proteins, occludin,
claudin-5 and ZO-1. Furthermore, a decrease in barrier function
evidenced by a decrease in TEER and an increase in monocyte
migration are observed in BMVECs exposed to ethanol. More-
over, the effects of ethanol on tight junction proteins and bar-
rier function were associated with increases in ROS, resulting
from ethanol metabolism, and increased calcium concentrations
and were prevented by antioxidant treatment or an inhibitor of
the intracellular calcium modulator, inositol 1,4,5-triphosphate
receptor (IP3R) (Haorah et al., 2005, 2007). The effects of ethanol
on the BBB in rodents however are less clear. Chronic treat-
ment of rats with 20% ethanol in drinking water for 12 months
produces BBB disruption as evidenced by increased BBB perme-
ability to endogenous IgG in the cortex (Ehrlich and Humpel,
2012). Similarly, 2 weeks of a 5% liquid alcohol diet increased
BBB permeability to radioactively labeled leptin (Pan et al., 2008).
In contrast, 7.5% ethanol in drinking water for 6 months had
no effect on permeability of the BBB to sucrose (Phillips, 1981)
nor did acute ethanol intoxication affect BBB permeability (Hem-
mingsen et al., 1980; Pan et al., 2008). Moreover, some stud-
ies suggest that acute ethanol may even protect against BBB
disruption resulting in stroke models (Zeng et al., 2012; Peng
et al., 2013), but others suggest a detrimental effect of ethanol
in HIV Tat and gp120-induced endothelial cell death and BBB
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permeability (Acheampong et al., 2002; Shiu et al., 2007). Thus,
ethanol alone can have protective or detrimental effects on BBB
function depending on dose and length of exposure. In combina-
tion with Meth, however, ethanol could potentiate Meth-induced
BBB disruption through its pro-inflammatory (Le Moine et al.,
1995; Mathurin et al., 2000) and pro-oxidant (Haorah et al., 2007)
effects.
HIV Infection
Meth use is also highly comorbid with HIV infection and the
combination of HIV infection and Meth can enhance BBB dis-
ruption. The BBB is affected byHIV infection and is also involved
in the progression of disease (for review, see Banks et al., 2006).
While HIV-induced increases in BBB permeability may not be
the sole reason for immune cells and virus infiltration into
the brain, HIV proteins act on BMECs and result in increased
neuroinflammation. Therefore, HIV infection could exacerbate
Meth-induced BBB damage.
The HIV proteins, Tat and gp120, alone or in combination,
cause BBB disruption via oxidative and inflammatory mecha-
nisms (Toborek et al., 2003; Price et al., 2005). Decreases in tight
junction proteins, claudin-1, claudin-5, and ZO-2 in BMVECs as
well as cytotoxicity of BMVECs were observed after treatment
with HIV Tat (Andras et al., 2003; Khan et al., 2003; Kim et al.,
2003). Furthermore, acute administration of gp-120 or cellular
expression of gp-120 caused the extravasation of Evans blue into
the brain and decreased the tight junction protein, claudin-5.
These alterations in BBB were associated with increased expres-
sion of MMP-2 and MMP-9. Moreover, when MMP expression
was inhibited via antioxidants or an NMDA receptor antagonist,
the gp-120-induced BBB disruption was prevented (Louboutin
et al., 2010). Therefore, HIV infection may exacerbate Meth-
induced BBB disruption via oxidative, inflammatory or glutamate
dependent mechanisms.
In fact, administration of the HIV proteins Tat and gp120
in combination with Meth to mice decreased tight junction
protein expression and increased BBB permeability to sodium-
fluorescein. These changes were associated with decreases in glu-
tathione and increased oxidation of lipids and proteins that were
attenuated by treatment with the antioxidant, N-acetylcysteine
amide (NACA) (Banerjee et al., 2010). This further supports the
interaction of HIV infection and Meth at the BBB as well as role
for oxidative stress in HIV and Meth-induced BBB disruption.
However, more investigation is necessary for a clear understand-
ing of the interaction of HIV infection and Meth in humans
as well as the role of inflammation and glutamate in HIV and
Meth-induced BBB disruption.
Consequences of Meth-Induced BBB
Disruption
The opening of the BBB can have broad and significant con-
sequences, particularly with regard to Meth use. These conse-
quences may manifest as enhanced vulnerability to other dis-
ease states that are co-morbid with Meth use such as stress, HIV
infection (Swan, 1997) and Hepatitis C. In fact, Meth users have
higher Hepatitis C and HIV viral titers in their brain as compared
with non-Meth users (Letendre et al., 2005, 2007; Nath, 2010).
Meth abuse is also associated with other infections. Meth
abuse produces what has been informally termed “Meth mouth.”
“Meth mouth” is characterized by extensive tooth decay, brux-
ism, and dry mouth (Rhodus and Little, 2008), all of which can
lead to bacterial infections and periodontal gum disease. A pri-
mary culprit of periodontal disease is Porphyromonas gingivalis
(P. gingivalis), a bacterium also linked to rheumatoid arthritis
and atherosclerosis (Iwai, 2009; Berthelot and Le Goff, 2010).
Few studies have examined its appearance and action in the
brain, although there is evidence that P. gingivalis can activate
microglial cells in culture (Shapira et al., 2002). Therefore, the
brains of Meth users could be extremely vulnerable to infection
by HIV, Hepatitis C and P. gingivalis, which can lead to enhanced
inflammatory responses and further brain damage.
More generally, Meth-induced BBB disruption may be the
cause of the cognitive decline and depression seen in Meth users.
BBB disruption is a pathological symptom of Alzheimer’s disease
and BBB disruption is thought to play a role in cognitive decline
and dementia (for review, see Van De Haar et al., 2014); however,
the exact mechanisms are unknown. BBB disruption also leads
to increases in infiltration of immune cells and inflammatory
mediators, which could affect normal brain physiology and func-
tion. For example, neuroinflammation is thought to precipitate
depression (for review, see Najjar et al., 2013) and may underlie
the depression associated with long-term use of Meth.
In contrast to the negative consequences of BBB disruption,
an opening of the BBB may facilitate the entry of therapeutics
that normally cannot enter the brain such as those used to treat
some neurodegenerative disorders or brain cancers. Thus, basic
knowledge about how Meth opens the BBB and the mechanisms
that underlie its acute and long-term effects may provide clues as
to how transient and persistent changes in the BBB can be dif-
ferentiated by other means than Meth exposure to facilitate acute
entry of therapeutic drugs into the brain.
Conclusion
Meth results in disruption of BBB structure and function and
the mechanisms that contribute to BBB disruption are similar
to those that are responsible for monoaminergic terminal dam-
age after Meth. However, more studies are needed to assign
a causative role for inflammation, glutamate and ammonia in
Meth-induced BBB disruption. Furthermore, comorbidities of
Meth including stress, poly-drug use and HIV infection could
exacerbate the damaging effects of Meth on the BBB. These find-
ings and possibilities highlight the urgency for new research
to identify the precise mechanisms that lead to the develop-
ment of therapeutics to treat the far-reaching and significant
consequences of Meth-induced BBB disruption.
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